Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
101-120 of 1,738 trials

Multiple Myeloma: Belantamab Treatment Study

We are investigating the safety and effectiveness of belantamab for treating multiple myeloma, both on its own and with other therapies. This study aims to find out how well it works for patients.

Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)HematologyOncology

Acute Myeloid Leukemia: Hydroxyurea and Valproic Acid Study

We are investigating a new treatment combination for patients with acute myeloid leukemia or high-risk myelodysplastic syndrome who cannot receive standard chemotherapy. The study will assess safety, effectiveness, and quality of life.

Acute Myeloid Leukemia6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Advanced Dedifferentiated Liposarcoma: Pemigatinib and Retifanlimab Study

We are studying the effects of two medications on patients with advanced dedifferentiated liposarcoma. The goal is to see if they improve treatment outcomes and quality of life.

Dedifferentiated Liposarcoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Isolated MMA: Long-Term Study of mRNA-3705

We are evaluating the long-term safety and effects of mRNA-3705 in individuals with Isolated MMA who have participated in earlier studies. This research aims to understand how the treatment impacts health and daily activities over time.

Methylmalonic AciduriaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal Medicine

Myasthenia Gravis: Rozanolixizumab for Kids

We are studying if rozanolixizumab is safe and effective for children with moderate to severe myasthenia gravis. This trial will help us understand how the medication works in young patients.

Myasthenia Gravis3-6 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesNeurologyPediatrics

Osteoporosis: Dasatinib and Quercetin Study

We are investigating whether a combination of dasatinib and quercetin can help improve bone health in patients with low bone mass. This study aims to see if it reduces bone loss more effectively than current treatments.

OsteoporosisOsteopenia3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyOrthopedics and Traumatology

Small Cell Lung Cancer: Niraparib with Immunotherapy

We are studying the effects of adding niraparib to immunotherapy for patients with SLFN11-positive small cell lung cancer. This research aims to see if it improves treatment after initial therapy.

Extensive Stage Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncologyPulmonology

Systemic Lupus Erythematosus: ESK-001 Treatment Study

We are investigating a new medication, ESK-001, for adults with systemic lupus erythematosus to see if it helps improve disease activity and is safe to use. Participants will receive either ESK-001 or a placebo in this study.

Systemic Lupus Erythematosus1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Calcific Aortic Valve Stenosis: Pelacarsen (TQJ230) Study

We are studying whether the medication pelacarsen can slow the progression of calcific aortic valve stenosis in patients with high lipoprotein(a) levels. This trial will help us understand its effects compared to a placebo.

Calcific Aortic Valve Stenosis>2 yearsEfficacy phase (II)16-20 visitsInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Semaglutide for Reducing GI Issues in Chemotherapy Patients

We are studying whether semaglutide can help lessen gastrointestinal problems in patients undergoing high-dose chemotherapy and stem cell transplantation. The trial also looks at its safety and effects on gut health.

Mucositis and Systemic Inflammation3-6 monthsEfficacy phase (II)Standard MedicinesCost ReimbursementGastroenterologyOncology

Chronic Graft-Versus-Host Disease: Axatilimab and Ruxolitinib Study

We are studying a new treatment combining axatilimab and ruxolitinib for people newly diagnosed with chronic graft-versus-host disease. The goal is to see if this combination is safe and effective in improving their condition.

Chronic Graft-Versus-Host Disease>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementAllergologyHematologyInternal Medicine

Atorvastatin for Preventing Episodic Migraines

We are studying whether atorvastatin can help reduce the frequency of episodic migraines in participants. This trial will also look at how well different doses work and any side effects that may occur.

Migraine3-6 monthsEfficacy phase (II)≤5 visitsStandard MedicinesNeurology

Chronic Migraine: Atorvastatin Study

We are investigating whether atorvastatin can help prevent chronic migraines in adults. The study will also assess how many people respond to the treatment and any potential side effects.

Chronic MigraineEfficacy phase (II)Standard MedicinesInternal MedicineNeurology

Kidney Disease: ALE.F02 Treatment Study

We are testing a new intravenous treatment, ALE.F02, for patients with rapidly progressive glomerulonephritis linked to AAV. The study aims to see if it can help protect kidney function and assess its safety.

Rapidly Progressive Glomerulonephritis6-12 monthsEfficacy phase (II)Investigational MedicinesInternal MedicineNephrology

Atopic Dermatitis: Amlitelimab Injection Study

We are evaluating the long-term safety and effectiveness of amlitelimab injections for individuals aged 12 and older with moderate to severe atopic dermatitis. This study aims to understand how the treatment impacts their symptoms and overall quality of life.

Atopic Dermatitis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyDermatology

Achondroplasia: TransCon CNP Treatment

We are studying a new weekly injection for children and adolescents with achondroplasia to see if it is safe and helps improve growth. This trial will help us understand the long-term effects of this treatment.

Achondroplasia1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyPediatrics

Hodgkin Lymphoma: Tislelizumab with Gemcitabine and Cisplatin

We are studying a combination of tislelizumab, gemcitabine, and cisplatin for patients with relapsed or refractory Hodgkin lymphoma. The goal is to see if this treatment improves survival and response rates.

Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Advanced NSCLC: Comparing Immune Treatments

We are studying two treatment strategies for patients with advanced non-small cell lung cancer to see which one works better. This trial also examines how these treatments affect the immune system and collects samples for future research.

Non-Small Cell Lung Cancer Stage IV>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyPulmonology

Infliximab for Non-Crohn Anal Fistulas

We are studying whether Infliximab can improve healing in patients with complex anal fistulas after surgery. This trial aims to find out if this treatment helps reduce complications and improve recovery.

Anal Fistula>2 yearsEfficacy phase (II)Standard MedicinesGastroenterologyInternal Medicine

High-Grade Glioma: Abemaciclib with Temozolomide

We are studying whether adding abemaciclib to temozolomide helps children and young adults with newly diagnosed high-grade glioma after radiotherapy. This trial compares the combination treatment to temozolomide alone.

GliomaEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPediatrics